Storys zum Thema Enterprises

Folgen
Keine Story zum Thema Enterprises mehr verpassen.
Filtern
  • 27.06.2011 – 07:03

    sanofi-aventis Group

    Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction

    Paris (ots/PRNewswire) - Sanofi announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus(R) and/or Apidra(R) with the insulin delivery device SoloSTAR(R) experienced greater treatment satisfaction, better quality of life and lower fear of hypoglycemia vs those using a premixed insulin product. The goal ...

  • 20.06.2011 – 20:03

    Agendia

    Agendia Postpones its IPO Due to Unfavourable Market Conditions

    Amsterdam and Irvine, California (ots/PRNewswire) - - Not for release, distribution or publication in whole or in part, directly or indirectly, into or in the United States, Australia, Canada, OR Japan Agendia (or the "Company"), a commercial-stage molecular cancer diagnostics company, announces the postponement of its Initial Public Offering ("IPO") that was due to price today. Agendia announced its intention to float on ...

  • 20.06.2011 – 15:47

    Bristol-Myers Squibb GmbH & Co. KGaA

    First-in-class Biologic Agent for Kidney Transplant Rejection Approved in Europe

    Paris (ots/PRNewswire) - - European Commission approves NULOJIX(R) (belatacept), in combination with corticosteroids and a mycophenolic acid and an interleukin-2 receptor antagonist at induction, for prophylaxis of graft rejection in adult patients receiving a kidney transplant - First new mode of action for prevention of graft rejection in kidney transplantation in a ...